Tissues and Organs (q-bio.TO)

Non-small cell lung cancer (NSCLC) is often intrinsically resistant to several first- and second-line therapeutics and can rapidly acquire further resistance after a patient begins receiving treatment. Treatment outcomes are therefore significantly impacted by the optimization of therapeutic scheduling. Previous preclinical research has suggested scheduling bevacizumab in sequence with combination antiproliferatives could significantly improve clinical outcomes. Mathematical modeling is a well-suited tool for investigating this proposed scheduling modification. To address this critical need, individual patient tumor data from 11 clinical trials in NSCLC has been collated and used to develop a semi-mechanistic model of NSCLC growth and response to the various therapeutics represented in those trials. Precise estimates of clinical parameters fundamental to cancer modeling have been produced - such as the rate of acquired resistance to various pharmaceuticals, the relationship between drug concentration and cancer cell death, as well as the fine temporal dynamics of vascular remodeling in response to bevacizumab. In a reserved portion of the dataset, this model was used to predict the efficacy of individual treatment time courses with a mean error rate of 59.7% after a single tumor measurement and 11.7% after three successive tumor measurements. A delay of 9.6 hours between pemetrexed-cisplatin and bevacizumab administration is predicted to optimize the benefit of sequential administration. At this gap, approximately 93.5% of simulated patients benefited from a gap in sequential administration compared with concomitant administration. Of those simulated patients, the mean improvement in tumor reduction was 20.7%. This result suggests that scheduling a modest gap between the administration of bevacizumab and its partner antiproliferatives could meaningfully improve patient outcomes in NSCLC.

This systematic review examines the synergistic and individual influences of resistance exercise, dietary protein supplementation, and sleep/recovery on muscle protein synthesis (MPS). Electronic databases such as Scopus, Google Scholar, and Web of Science were extensively used. Studies were selected based on relevance to the criteria and were ensured to be directly applicable to the objectives. Research indicates that a protein dose of 20 to 25 grams maximally stimulates MPS post-resistance training. It is observed that physically frail individuals aged 76 to 92 and middle-aged adults aged 62 to 74 have lower mixed muscle protein synthetic rates than individuals aged 20 to 32. High-whey protein and leucine-enriched supplements enhance MPS more efficiently than standard dairy products in older adults engaged in resistance programs. Similarly, protein intake before sleep boosts overnight MPS rates, which helps prevent muscle loss associated with sleep debt, exercise-induced damage, and muscle-wasting conditions like sarcopenia and cachexia. Resistance exercise is a functional intervention to achieve muscular adaptation and improve function. Future research should focus on variables such as fluctuating fitness levels, age groups, genetics, and lifestyle factors to generate more accurate and beneficial results.